COMP <GO>
LIMN vs CLDI // PIOTROSKI F-SCORE QUALITY
Liminatus Pharma Inc. (Class A) (NASDAQ) VS. Calidi Biotherapeutics Inc. (NYSE) • 15-METRIC TALLY: LIMN 2
— CLDI 1
▲ PIOTROSKI F-SCORE QUALITY LEADER: CLDI
LAST: $2.90 (-0.86%) • MKT CAP: $3.9M
piotroski-score
1/9
LAST: $0.67 (-4.29%) • MKT CAP: $2.5M
piotroski-score
2/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIMN VS. CLDI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIMN | CLDI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 1/9 | 2/9 | -1.00 | CLDI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.4 | 28.2 | +6.17 | LIMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.9M | $2.5M | $1.4M | LIMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIMN REV | CLDI REV | LIMN GROSS % | CLDI GROSS % | LIMN FCF | CLDI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$10.0M | -$21.3M |
| FY 2024 | $0 | $0 | — | — | -$1.5M | -$19.7M |
| FY 2023 | — | $0 | — | — | — | -$27.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIMN // BETA —
CLDI // BETA —